These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1212 related articles for article (PubMed ID: 30777870)

  • 21. Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.
    Drapkin BJ; Farago AF
    Trends Pharmacol Sci; 2019 May; 40(5):295-297. PubMed ID: 30975441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting DNA damage in SCLC.
    Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
    Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
    Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 25. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
    Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
    Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
    Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
    J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
    Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
    Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
    Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
    Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
    Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.